Company profile
Arvinas Inc.
ARVN (EDGAR registrant "ARVINAS, INC." with listed ticker ARVN [resolved 2026-08-05 by resolve-null-is-public; source: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001655759])
Share price · ARVN
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Unadjusted for historical splits · Data via Databento
Assets
(2 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | Estrogen receptorSmall molecule | HR+/HER2- Breast Cancer HR+/HER2- Metastatic Breast Cancer | |
| Phase 2 | KRAS G12DSmall molecule | Non-Small Cell Lung Cancer |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.
Insider transactions
Unlock insider transactions
Research includes SEC Form 4 insider transactions — filed buys, sells, awards and exercises linked to the underlying filings.
Institutional holders
Unlock institutional holders
Research includes quarterly SEC 13F institutional ownership — top holders, aggregate positions and quarter-over-quarter context.